Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07179679 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

StatusRecruiting
PhasePhase 1
Started2025-12-09
View on ClinicalTrials.gov ↗

Amendment history

2025-12-10
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-10→confirmed 2025-12-09
Study sites3→14
2025-09-16
Original filing
TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody，and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells. TQB2934 for injection (subcutaneous injection) is intended for the treatment of patients with multiple myeloma.
Trial Details
NCT Number NCT07179679
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Multiple Myeloma
Enrollment 42 participants
Start Date 2025-12-09
Primary Completion 2027-10 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-11